Day: May 14, 2025

Shenzhen, May 14, 2025 (GLOBE NEWSWIRE) — MicroAlgo Inc. Announces Research on Quantum Information Recursive Optimization (QIRO) Algorithm, for Combinatorial Optimization Problems to Expand and Solve New Ideas Shenzhen, May. 14, 2025––MicroAlgo Inc. (the “Company” or “MicroAlgo”) (NASDAQ: MLGO), today announced the research of the Quantum Information Recursive Optimization (QIRO) algorithm, which aims to provide a new approach to combinatorial optimization problems by leveraging the power of quantum computing. The Quantum Information Recursive Optimization (QIRO) algorithm is an optimization algorithm based on quantum computers, designed to tackle complex combinatorial optimization problems. This algorithm combines the concepts of quantum computing and recursive algorithms, utilizing the parallel computing...

Media Release COPENHAGEN, Denmark; May 14, 2025Data from 14 abstracts highlight the depth, breadth, and strength of Genmab’s comprehensive epcoritamab development program across multiple patient populations and treatment settingsGenmab A/S (Nasdaq: GMAB) announced today that it will present 14 abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, as a monotherapy and in combination across disease settings in patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) at the 30th European Hematology Association (EHA) Congress, being held in Milan, Italy, and virtually, June 12-15, 2025. Two oral presentations will feature data from the Phase 1/2 EPCORE® NHL-2 trial evaluating epcoritamab plus rituximab and ifosfamide-carboplatin-etoposide (R-ICE) in patients with relapsed/refractory...

– Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r AML patients selected for oral presentation on Thursday, June 12th – – Updated dataset to be presented in oral presentation at EHA2025 Congress – SAN DIEGO and TOKYO, May 14, 2025 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) and Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) today announced that an abstract highlighting clinical data from the KOMET-007 combination trial of ziftomenib, a once-daily, oral investigational menin inhibitor, has been accepted for presentation at the upcoming 2025 European Hematology Association (EHA) Congress, to be held in Milan, Italy, from June 12-15, 2025. KOMET-007 is a multicenter Phase 1 trial of ziftomenib in combination with standards of care, including cytarabine plus daunorubicin (7+3) and venetoclax/azacitidine (ven/aza),...

CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that new data on the company’s PK activators, mitapivat and tebapivat, will be featured in oral and poster presentations during the 30th European Hematology Association (EHA) Congress (EHA 2025) in Milan, Italy, June 12-15, 2025. “The clinical results and scientific insights being presented at EHA add to the robust body of efficacy and safety data demonstrating the promise of PK activation in treating both adults and children with rare blood disorders,” said Sarah Gheuens, M.D., Ph.D., Chief Medical Officer and Head of R&D, Agios. “The presentations span serious conditions with limited or no treatment options,...

Annual General Meeting of Shareholders –        Approval of a gross dividend of € 1.90 per share–        Approval of the proposed appointments and reappointments of Directors On Wednesday 14 May 2025, Bekaert’s Annual General Meeting of Shareholders took place chaired by Jürgen Tinggren, Chairman of the Board of Directors. The following main subjects were considered. The meeting approved the balance sheet and the income statement per 31 December 2024, as submitted by the Board of Directors, including the distribution of a gross dividend of € 1.90 per share.The dividend ex-date is 16 May 2025. The dividend will be payable on 20 May 2025. The meeting acknowledged the 2024 annual report of the Board of Directors and approved the remuneration report for the year 2024, as well as the remuneration policy applicable to the non-executive...

MONTREAL, May 14, 2025 (GLOBE NEWSWIRE) — Fiera Capital Corporation (“Fiera Capital” or the “Company”) (TSX: FSZ) is pleased to announce that it has entered into an agreement with Scotiabank, CIBC Capital Markets, Desjardins Capital Markets and RBC Capital Markets, as joint bookrunners, on behalf of a syndicate of underwriters which also included National Bank Financial Inc., BMO Capital Markets, TD Securities Inc., Canaccord Genuity Corp., iA Private Wealth Inc. and Raymond James Ltd. (collectively, the “Underwriters”), whereby the Underwriters have agreed to purchase $60 million aggregate principal amount of senior subordinated unsecured debentures due June 30, 2030 (the “Debentures”) at a price of $1,000 per Debenture (the “Offering”). Fiera Capital has also granted...

SAN FRANCISCO, May 14, 2025 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that data from the Company’s ongoing Phase 1a/b clinical trial of bexobrutideg (NX-5948) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia will be presented at two major upcoming scientific conferences. Data will be featured in two posters at the European Hematology Association 2025 Congress (EHA 2025), taking place June 12–15, 2025, in Milan, Italy, and in an oral presentation and poster at the 18th International Conference on Malignant Lymphoma (18-ICML), to be held June 17–21, 2025, in Lugano, Switzerland. EHA 2025 Presentation...